Can a better understanding of frailty improve the quality of life of patients with fibrotic interstitial lung diseases?

Management of progressive fibrotic interstitial lung diseases (ILDs) has long been limited to compensatory oxygen therapy and/or corticosteroids, but work in recent years has established the efficacy of new antifibrotic treatments in slowing the decline of patients with idiopathic pulmonary fibrosis [1]. However, many factors contribute to the tolerance and efficacy of new drugs in patients with ILDs.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research